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AP2α controls the dynamic balance between miR-126&126*
and miR-221&222 during melanoma progression
N Felli1,3, MC Errico1,3, F Pedini1, M Petrini1, R Puglisi1, M Bellenghi1, A Boe1, F Felicetti1, G Mattia1, A De Feo1, L Bottero1, C Tripodo2 and
A Carè1
Accumulating evidences have shown the association between aberrantly expressed microRNAs (miRs) and cancer, where these
small regulatory RNAs appear to dictate the cell fate by regulating all the main biological processes. We demonstrated the
responsibility of the circuitry connecting the oncomiR-221&222 with the tumor suppressors miR-126&126* in melanoma
development and progression. According to the inverse correlation between endogenous miR-221&222 and miR-126&126*,
respectively increasing or decreasing with malignancy, their enforced expression or silencing was sufﬁcient for a reciprocal
regulation. In line with the opposite roles of these miRs, protein analyses conﬁrmed the reverse expression pattern of
miR-126&126*-targeted genes that were induced by miR-221&222. Looking for a central player in this complex network, we
revealed the dual regulation of AP2α, on one side directly targeted by miR-221&222 and on the other a transcriptional activator of
miR-126&126*. We showed the chance of restoring miR-126&126* expression in metastatic melanoma to reduce the amount of
mature intracellular heparin-binding EGF like growth factor, thus preventing promyelocytic leukemia zinc ﬁnger delocalization and
maintaining its repression on miR-221&222 promoter. Thus, the low-residual quantity of these two miRs assures the release of AP2α
expression, which in turn binds to and induces miR-126&126* transcription. All together these results point to an unbalanced ratio
functional to melanoma malignancy between these two couples of miRs. During progression this balance gradually moves from
miR-126&126* toward miR-221&222. This circuitry, besides conﬁrming the central role of AP2α in orchestrating melanoma
development and/or progression, further displays the signiﬁcance of these miRs in cancer and the option of utilizing them for novel
therapeutics.
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INTRODUCTION
Melanoma is a highly aggressive form of skin cancer mostly
curable in its early stages, but no more responsive to therapies in
the metastatic phase fronting very poor prognosis.1 The rate of
this neoplasm is rapidly rising in the white population worldwide
and epidemiological studies point out genetic and phenotypic
traits, risk behaviors and environmental factors as important
elements for its incidence.2
The discovery of frequent genetic alterations provided the
opportunity to improve the conventional therapies by using
speciﬁc inhibitors of key target proteins.3 Unfortunately, the onset
of tumor resistance after single agent treatment represents a
signiﬁcant limit for these approaches inducing to search multi-
factor strategies.4,5 In this context, the emerging role of miRs as
new players in melanoma disease may represent one exciting and
hopeful therapeutic challenge.6 MiRs are a class of small
noncoding RNA molecules that regulate gene expression, mainly
at post-transcriptional level. One major advantage of miR
therapeutic use is represented by the low toxicity expected from
the re-expression of physiological molecules. In addition their
simultaneous involvement in different pathways might give
strength to their effects, virtually reducing the risk of tumor
resistance.7 On the other hand, their direct action on several
targets/pathways obviously suggests the requirement of an in
depth molecular analysis before any possible translation to
therapy.
A number of studies demonstrated the pro-tumorigenic role of
miR-221&222 and the tumor suppressor activity of miR-
-126&126*.8–11 In melanoma progression the enhanced expression
of miR-221&222 activates several fundamental pathways, inducing
cell survival and blocking melanogenesis.12 On the contrary the
reduced expression of miR-126&126* in advanced melanomas
leads to the up-modulation of ADAM9 and MMP7 proteases,
which in turn increase heparin-binding EGF like growth factor (HB-
EGF) shedding and production of the intracellular fragment HB-
EGF-C.9,13,14 As a major step in understanding how this impaired
miR-126&126* expression spreads to downstream molecules
promoting tumorigenesis, we have here demonstrated that HB-
EGF-C binds and delocalizes the promyelocytic leukemia zinc
ﬁnger protein (PLZF), preventing the negative transcriptional
regulation of its target genes.15,16 Speciﬁcally, in normal human
epidermal melanocytes (NHEM) and primary vertical growth phase
melanomas PLZF has its antineoplastic function repressing the
oncomiR-221&222.8,17
In view of the opposite patterns induced by enforcedly
expressing miR-126&126* or miR-221&222 in melanoma and
considering that some miR-221&222-targeted genes are upregu-
lated by miR-126&126* and vice versa,8–10 we focused our
attention on the possibility of a cross-regulation between these
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two couples of miRs. As a key element in this regulatory cross-talk
we identiﬁed AP2α transcription factor whose key role in
melanoma was already well known, but only recently associated
with miR transcription.18–20
Here we demonstrated the essential dual function of AP2α that
acts as a positive transcriptional regulator of miR-126&126* by
directly binding to the promoter of its host gene EGFL7, and it is
also directly targeted by miR-221&222. These ﬁndings shed a new
light on AP2α, further conﬁrming its fundamental role in
melanoma progression where it represents a rheostat in miR-
-126&126* and miR-221&222 balanced regulation.
RESULTS
miR-126&126* and miR-221&222 expression patterns are inversely
related during melanoma progression
Previous published data showed the opposite functions of
miR-126&126* and miR-221&222 in melanoma progression, where
they act as tumor suppressors and oncomiRs respectively.8,9
To deeply investigate the relationship between these two couples
of miRs, we compared their expression levels in a panel of
melanoma cell lines, representing different stages of progression.
Quantitative real-time RT–PCR (qRT–PCR) revealed that the levels
of miR-126&126* were inversely related to those of miR-221&222.
Particularly, miR-126&126* were highly expressed in NHEM and
primary vertical growth phase melanomas and dropped in
subcutaneous and lymph-node metastases. Conversely, miR-
-221&222 were almost undetectable in NHEM and gradually
increased during progression (Figure 1a).
The initial hypothesis of a cross regulation between miR-
-126&126* and miR-221&222 was sustained by the strong
suppression of miR-221 and miR-222 observed in miR-126&126*-
transduced A375M metastatic melanoma cell line (Figure 1b, left)
and by the induction of miR-126&126* when miR-221&222 were
silenced (Figure 1b, right). The same coregulation was obtained in
Me1402/R melanoma, as either the enforced expression or the
abrogation of miR-221 or miR-222 clearly down- and up-
modulated miR-126 and miR-126* levels (Figure 1c). Similar results
were detected in Mel501 melanoma endogenously expressing
high levels of miR-126&126* and low miR-221&222 (Figure 1a).
Indeed either miR-221&222 enforced expression or miR-126&126*
abrogation were able to induce the negative feedback between
these couples of miRs, showing the possibility of further increase
miR-126&126* in primary tumor cells (Figure 1d). The opposite
roles of these two clustered miRs were demonstrated by the
inverse expression pattern of several pro-oncogenic factors which
are targeted by miR-126&126* and increased by miR-221&222
(that is, ADAM9, MMP7 and OPN; Supplementary Figure 1).
HB-EGF-C intracellular fragment interacts with and mediates PLZF
delocalization into the cytoplasm
We previously reported that miR-126&126*, through ADAM9 and
MMP7 regulation, interfere with the activating cleavage of the
HB-EGF precursor, impairing the HB-EGF-C intracellular fragment
production.9 This portion is known to enter the nucleus where it
binds and delocalizes important transcription regulators, like PLZF,
Figure 1. miR-126&126* and miR-221&222 expression patterns are
inversely related during melanoma progression. qRT–PCR analysis
of (a) endogenous expression levels of miR-126&-126* and
miR-221&222 in normal melanocytes (NHEM) and melanoma cell
lines. (b) A375M cells transduced with miR-126&126* (left) or
silenced for miR-221&222 (right). (c) Me1402/R overexpressing
miR-221&222 (left) or silenced (right) for miR-221&222. (d) Mel501
transduced with miR-221 or miR-222 (left) or after inhibition of
miR-126&126* (right). Non-targeting (non targ) oligomers were
included as negative controls. Relative miR expression levels were
normalized on RNU6B levels. Columns, mean± s.d. of at least three
independent experiments. *Po0.05, **Po0.01.
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preventing their repressive functions.15,16 The inhibitory role of
PLZF on miR-221&222 expression8 prompted us to speculate that
in advanced melanoma the low or absent level of miR-126&126*,
releasing the overexpression of ADAM9 and MMP7, should result
in an increased shedding of pro-HB-EGF. As a consequence, the
nuclear repressive function of PLZF should be abrogated and
miR-221&222 transcription unblocked. To experimentally conﬁrm
this hypothesis, we evaluated the effects of MMP7 and ADAM9
silencing on miR-221&222 expression, if any. Indeed low levels of
these proteases led to miR-221&222 reduction (Figure 2a), thus
supporting the functional involvement of these factors in closing
the circuitry between miR-126&126* with miR-221&222.
In agreement with this assumption, experiments of coimmu-
noprecipitation conﬁrmed the direct interaction between PLZF
and HB-EGF-C in advanced, but not in early primary melanoma
cells (Figure 2b). In view of a different compartmentalization of
PLZF, melanoma cells transduced or not with miR-126&126* were
treated with the phorbolester Phorbol-12-myristate-13-acetate-
(PMA), known to boost HB-EGF cleavage through metalloprotease
activation.13,14 Indeed the translocation of PLZF from the nucleus
into the cytoplasm observed in PMA treated control melanoma
was impaired by the enforced expression of miR-126&126*, as
conﬁrmed by the permanence of this protein in the nuclear
fractions (Figure 2c).
AP2α transcription factor is directly regulated by miR-221&222
Searching for proteins predicted as putative targets of
miR-221&222 and speciﬁcally involved in melanoma progression,
among a number of options reported by the TargetScan speciﬁc
software (Whitehead Inst., Cambridge, MA, USA), we focused on
AP2α, a transcription factor whose expression is lost in advanced
melanoma cell lines.20,21 To verify the hypothesis of AP2α as a
direct target of miR-221&222, we analyzed its expression level in
NHEM and some differently staged melanoma cell lines. In line
with published data,22 expression analyses showed that AP2α was
highly expressed in NHEM, maintaining a virtually steady state in
primary melanoma cells and disappearing in metastatic mela-
noma cells (Figure 3a). As expected for a miR-regulatory system,
AP2α protein expression resulted inversely related to miR-
-221&222 levels (Figure 3a). To verify the functional binding of
miR-221&222 to the putative conserved site present in the 3′UTR
of AP2α, we performed a series of luciferase assays. The AP2α 3′
UTR, containing either the wild-type or mutated miR-221&222-
binding sequence, was cloned downstream to the luciferase open
reading frame (Figure 3b). Constructs were cotransfected into the
293FT and Me1007 cell lines with either miR-221&222 or a non-
targeting oligonucleotide. Results showed a signiﬁcant miR-
-221&222-dependent inhibition of the luciferase activity (~40%
reduction in 293FT and 20–40% in Me1007 cells). Importantly,
mutation of six bases in the seed sequence totally abrogated
miR-221&222-dependent repression in both cell lines (Figure 3c).
All together these experiments demonstrated that miR-221&222
directly interact with and repress AP2α. Accordingly, miR-221 or
miR-222 enforced expression in Me1007 and Me1402/R primary
melanoma cells strongly suppressed AP2α (Figure 3d). Signiﬁcant
increases of AP2α levels were obtained in Me1402/R and A375M
Figure 2. ADAM9 and MMP7 regulate miR-221&222 expression through HB-EGF-C/PLZF interaction and delocalization. (a) Western
blot validation of ADAM9 and MMP7 silencing (left) and qRT–PCR analysis of the resulting miR-221&222 downmodulation (right).
(b) Coimmunoprecipitation of HB-EGF-C and PLZF in Me665/1 and Me1007 cell lysates. Proteins were immunoprecipitated with PLZF Ab and
immunoblotted with HB-EGF-C and PLZF Abs. (c) Representative WB analysis of PLZF in control untreated and PMA-treated miR-126&126* vs
TripZ vector-transduced A375M cell line. PLZF was evaluated in nuclear and cytoplasmic extracts at t= 0 as baseline control and then after 1 or
2 h of PMA. Nucleolin and Tubulin were assessed to conﬁrm protein puriﬁcation and amounts. PLZF export from the nucleus into the
cytoplasm was induced by PMA in control, but not in miR-126&126*-transduced cells. Ab, Antibody; CE, cytoplasmic extracts; NE, nuclear
extracts; PMA, Phorbol-12-myristate-13-acetate; WB, western blot *Po0.05; **Po0.01.
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melanomas as a consequence of the simultaneous abrogation of
miR-221&222 (Figure 3e).
EGFL7/miR-126&126* promoter regulation
To dissect the complex circuitry possibly connecting miR-
126&126* and miR-221&222, we focused our attention on
EGFL7/miR-126&126* putative promoters. The stem–loop sequence
harboring miR-126&126* is included in the intron 7 of the EGFL7
gene located on chromosome 9.23 EGFL7 gene encodes for a
single protein although derived from T1 (NM_016215) or T2
(NM_201446) isoforms, differing in the 5′ untranslated region
(Figure 4a). Previous data demonstrated the CpG island localized
in the T2 proximal promoter of EGFL7 and miR-126 (Prom2) as the
Figure 3. AP2α targeting by miR-221&222. (a) WB analysis of AP2α with relative densitometric evaluation and miR-221 and -222 levels in
normal melanocytes (NHEM) and melanoma cell lines. (b) Nucleotide pairing between AP2α 3′UTR and miR-221 and -222 is shown by bars.
The seed sequence is indicated in bold, while lower case letters with asterisks represent the mutated nucleotides. (c) Luciferase reporter assay
performed in 293FT (left) and Me1007 (right) cell lines by cotransfecting miR-221 or -222 in the presence of the AP2α 3′UTR. As controls,
mutated 3′UTR sequences and a non-targeting oligomer were also included. (d) qRT–PCR (left) and representative WB analysis (right) of AP2α
in Me1007 (top) and Me1402/R (bottom) control Tween vector vs miR-221- or 222-transduced cells. (e) Representative WB analysis of AP2α in
anti-miR-221&222-transfected Me1402/R and A375M melanoma cells. GAPDH and actin are the internal controls. Non-targeting oligomers
were also included as negative controls. Columns, mean± s.d. of at least three independent experiments. *Po0.05, **Po0.01. LUC, luciferase;
Mut, mutated; non targ, non-targeting; WB, western blot.
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main regulatory target of epigenetic mechanisms, being miR-126
apparently dependent on promoter hypermethylation of its host
gene.24–26 On this basis we evaluated by bisulﬁte genomic
sequencing the CpG methylation proﬁle in our melanoma cell
lines. Unexpectedly metastatic samples expressing lower levels of
miR-126&126* did not result hypermethylated, but showed a
methylation level similar to that of normal melanocytes and lower
than primary melanoma cell lines (Figure 4b). Accordingly, the
5-aza-2′-deoxycytidine (5-aza-dC) treatment of A375M and
Me665/1 metastatic cells induced a very low increment of
miR-126 compared with primary Me1402/R cells (Figure 4c). To
verify a possible alteration of the chromatin structure, we also
treated primary and metastatic melanoma cells with the histone
deacetylase inhibitor trichostatin A (TSA) and with a combination
of 5-aza-dC and TSA. As reported, miR-126 was again induced in
primary melanoma but not in metastatic A375M and Me665/1 cells
(Figure 4a). No signiﬁcant increment of EGFL7 was obtained in the
different treatment conditions in both cell lines (Figure 4d and
data not shown). A very strong raise of p21 protein was included
as a positive control of 5-aza-dC and TSA functionality
(Figure 4d).27 All together these evidences prompted us to look
for mechanisms other than epigenetic as responsible for miR-
-126&126* downmodulation in metastatic melanoma.
AP2α binds and regulates the EGFL7/miR-126&126* promoter
Further analysis of the putative miR-126&126* promoter regions
(NC_000009, 139551234-139569202) showed an interesting cis-
regulatory sequence, upstream to both T1 and T2 EGFL7 isoforms.
This sequence (Prom1) was already reported to promote the
expression of the T1 EGFL7 isoform.28 Interestingly, an in silico
analysis (Transfact software, www.gene-regulation.com) revealed
the presence of ﬁve potential AP2α-binding sites (BS) in this
region (Figure 5a). To demonstrate the direct action of AP2α on
these cis-regulatory sequences, we cloned this genome fragment
into the pGL3-basic reporter vector. Starting from a 0.9 kb
fragment (−799/+121) including ﬁve AP2α BSs, we also generated
a smaller one (−140/+121) containing three AP2α BSs, one of
which (BS3) near to the transcription start site (considering the T1
EGFL7 start site as +1) (see Materials and methods section for
details). Each construct was cotransfected with the AP2α over-
expressing vector in either 293FT or Me1402/R cell lines. As shown
in Figure 5b, the luciferase activity was strongly induced when the
exogenous AP2α acts on the whole fragment (−799/+121)
(4.36 ± 0.25 fold increase of AP2α vs Tween in 293FT and
1.9 ± 0.15 in Me1402/R). Interestingly a similar increase was
obtained in both cell lines with the small fragment (−138/+121;
4.4 ± 0.07 fold increase of AP2α vs Tween in 293FT and 1.97 ± 0.13
in Me1402/R) suggesting a major role of BS 1–3. Consistent results
were obtained by transfecting these constructs with either Dsi-
AP2α or Dsi-scr (RNA scrambled control) sequences into the 293FT
and Me1402/R cell lines. In both cases the luciferase activity was
reduced either in presence of the long (1.96 ± 0.3 fold decrease in
293FT and 1.42 ± 0.2 fold in Me1402/R) or of the small fragment
(1.76±0.06-fold decrease in 293FT and 1.4±0.2 fold in Me1402/R;
Figure 5c). Based on these results and to identify the speciﬁc
efﬁciency of each AP2α BS, we performed mutagenesis experi-
ments for each of the ﬁve sites. Results suggested the association
of most of the AP2α activity with BS3 plus a very small effect
linked to BS4 (Figure 5d). The in vivo interaction between these
putative cis-regulatory elements and AP2α protein was conﬁrmed
by chromatin immunoprecipitation assays in the Me1402/R cells:
PCR ampliﬁcations of unsheared input genomic DNA and anti-
AP2α antibody-mediated reaction revealed a signiﬁcant binding at
all the analyzed BSs compared with product obtained by
immunoprecipitation with an irrelevant antibody as negative
control. Although chromatin immunoprecipitation cannot be
considered a quantitative analysis, BS4 and BS3 displayed the
stronger bands possibly suggesting a higher afﬁnity of AP2α to
these sites (Figure 5e).
AP2α transcription factor regulates miR-126&126* expression
To better understand the role of AP2α, we evaluated its
effectiveness in regulating miR-126&126* expression. To this end
we used a lentiviral system to constitutively express AP2α in
Figure 4. Epigenetic regulation of miR-126 and its host gene
EGFL7. (a) Schematic depiction of the location of the miR-126 gene
within an intron of the EGFL7 gene. Promoter 1 and Promoter 2. (b)
Bisulphite genomic sequencing analysis of the CpG islands in the
EGFL7 promoter 2 of normal melanocytes (NHEM), Me1402/R and
A375M melanoma cell lines. Horizontal lines of circles represent
each sequenced clone (5–14 independent analyses for each sample);
percentages represent the number of methylated CpG islands
respect to the totality present in the sequenced fragment. Unﬁlled
(white) and ﬁlled (black) circles represent unmethylated and
methylated CpGs, respectively. (c) miR-126 expression in Me1402/
R, A375M and Me665/1 cells after treatment of 5′-aza-dC and TSA
evaluated as fold increase respect to untreated cells. RNU6B was
used as a control. (d) Representative WB analysis of EGFL7 in A375M
cell line treated with 5′-aza-dC and/or TSA. P21 induction was used
as a positive control of treatment effectiveness. 5′-aza-dC, 5′-aza-2′-
deoxycytidine; Prom1, promoter 1; Prom2, promoter 2; WB,
western blot.
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Me1007 and Me1402/R melanoma cell lines, selected for their low,
but detectable levels of both miR-221&222 and for high or
intermediate miR-126&126*, respectively. The overexpression of
AP2α was conﬁrmed by qRT–PCR and western blot analysis at day
2 post infection (AP2α vs Tween) (Supplementary Figures 2a and b).
AP2α-transduced Me1007 and Me1402/R cells showed a burst of
miR-126&126* expression (14- and 15-fold and 6- and 10-fold
increase, respectively; Figures 6a and b, right). An opposite trend
was detected in Me1402/R for miR-221&222 whose strong
decrease (Figure 6b, middle) supported the hypothesis of the
AP2α-mediated inverse cross-regulation between the two
groups of miRs. As a control of miR-126&126* induction and
functionality in AP2α-overexpressing Me1402/R, we observed
a substantial reduction of PIK3R2, a validated target of
miR-126&126* (Supplementary Figure 2a, right).29 Accordingly,
miR-126&126* downregulation was the consequence of AP2α
silencing in Me1007 and Me1402/R primary melanoma cell
lines (Figures 6a and b, right; and Supplementary Figure 2c).
Considering an important goal restoring miR-126&126* expression
in metastatic melanoma cells, we lentivirally transduced AP2α also
in the A375M cell line, getting a parallel signiﬁcant induction of
miR-126&126* (5- and 2.4-fold; Figure 6c and Supplementary
Figure 2d). An increment of miR-126&126* level was also achieved
in NHEM as a consequence of AP2α enforced expression
(Supplementary Figure 2e). Finally, the actual effectiveness of this
regulatory pathway was revealed by in situ hybridization of
miR-126 and miR-221&222 and by immunohistochemistry of AP2α
in bioptic specimens from patients. Results conﬁrmed the direct
association of AP2α with miR-126 and its inverse relationship
with miR-221&222 (Figure 6d). Additional analyses performed by
in situ hybridization on representative bioptic samples, including
tumor-adjacent normal tissues, compound melanocytic nevi,
primary melanomas Clark’s levels I–III, as well as subcutaneous
and lymph node metastases, further supported the inverse
correlation between these microRNAs (Supplementary Figure 3
and data not shown).
EGFL7 expression results from the balance between AP2α
transcriptional induction and miR-126&126*targeting
To support the hypothesis that the above reported AP2α cis-
elements regulating miR-126&126* expression might also be
functional to EGFL7 transcription, we evaluated the amounts of
EGFL7 in Me1007 and A375M cell lines, representative of early and
advanced stages. As expected, AP2α enforced expression induced
a marked up-modulation of EGFL7 at mRNA and protein levels in
both melanoma cell lines respect to control vector-transduced
and untreated cells (Figure 7a). In line with a recent work showing
that EGFL7 was targeted by miR-126&126*,30 we also found a
signiﬁcant, although moderate, reduction of EGFL7 protein in
Me665/1 and A375M overexpressing miR-126&126* respect to
control cells (Supplementary Figure 4a). Conversely, 48 h treat-
ment of primary and metastatic melanoma cells with anti-
miR-126&126* locked-nucleic-acid oligonucleotides induced a
signiﬁcant increase of EGFL7 protein (Supplementary Figure 4b).
Consistent with these results, we observed an increment of EGFL7
in metastatic melanoma cells compared with primary melanoma
and normal melanocytes, perhaps due to reduced miR-126&126*-
mediated post-transcriptional inhibition (Supplementary Figure 4c).
DISCUSSION
Melanoma is one of the most aggressive human cancers, being
resistant to therapy in advanced stages.1–5 Therefore, under-
standing the mechanisms regulating the switch from primary to
metastatic tumor as well as cell resistance to therapies would
be a crucial goal. The role of deregulated transcription factor
activity in determining tumorigenicity and metastatic potential
Figure 5. EGFL7/miR-126&126* promoter regulation. (a) Schematic
illustration of the genomic region representing the promoter 1 of
EGFL7. BS1-2, BS3, BS4 and BS5 indicate the AP2α BSs. (b) Promoter
luciferase assays performed in the 293FT and Me1402/R cells
transfected with AP2α. As control, the empty vector Tween was
included. (c) Promoter luciferase assays performed in the 293FT and
Me1402/R cells transfected with either Dsi-AP2α or Dsi-scr negative
control. (d) As control of the APα BSs speciﬁcity, point mutations
were inserted in the core-binding sequences and promoter
luciferase assay performed. (e) Chromatin immunoprecipitation
assay performed in Me1402/R cells with anti-AP2α antibodies and
analyzed by semiquantitative PCR. Columns, mean± s.d. of at least
three independent experiments. *Po0.05, **Po0.01, ***Po0.001.
Mut, mutated.
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was extensively studied.20,21 Likewise, the involvement of miRs in
cancer, including melanoma, is by now widely accepted.6,7
We have here investigated the option of a negative feedback
loop connecting miR-126&126* and miR-221&222 starting from
their inversely correlated expressions and opposite functions, the
former being tumor suppressors and the latter oncomiRs.
Accordingly, miR-126&126* overexpression in melanoma cells
was sufﬁcient to strongly downregulate miR-221&222 and vice
versa (Figure 1). In line with the contrasting roles of these two
clustered miRs, protein analyses demonstrated the inverse
expression pattern of several pro-oncogenic factors, targeted by
miR-126&126* (that is, ADAM9, MMP7 and OPN) and induced by
miR-221&222 (Supplementary Figure 1). On the other hand, some
differentiation and melanogenesis-linked molecules (that is, c-KIT,
MITF and TRP1) rose in a miR-126&126*-dependent manner and
were directly or indirectly repressed by oncomiR-221&222.8,9
We recently demonstrated in melanoma progression that
miR-126&126* downregulation has its oncogenic role unblocking
ADAM9 and MMP7 expression consequently activating the
HB-EGF.9 Besides its triggering of the EGF receptor, the HB-EGF-C
terminal portion, produced by ectodomain shedding, is known to
enter the nucleus where it binds and delocalizes PLZF.15,16 Among
several other targets, we previously described PLZF as a
transcriptional repressor of miR-221&222.8 Here we demonstrated
the physical interaction between HB-EGF-C and PLZF in the
nucleus of advanced melanoma followed by the rapid delocaliza-
tion of PLZF into the cytoplasm (Figures 2b and c). Indeed, as a
result of the low proteolytic activation of HB-EGF in miR-
-126&126*-overexpressing cells, PLZF remained on miR-221&222
promoter blocking its transcription (Figure 2c). Interestingly, a
similar regulatory pathway was described in colon cancer cells
where the TPA-induced nuclear translocation of HB-EGF-C and
Figure 6. AP2α-dependent regulation of miR-126&126* and miR-221&222. qRT–PCR evaluations of (a) miR-126&126* (left), and miR-221&-222
(middle) in AP2α-overexpressing Me1402/R cell line and miR-126&126* after AP2α silencing (right). (b) miR-126&126* as a consequence of
AP2α enforced expression or silencing in Me1007. (c) miR-126&126* in AP2α-transduced A375M cells. Samples were normalized on RNU6B
levels. Columns, mean± s.d. of at least three independent experiments. **Po0.01, ***Po0.001. (d) In situ hybridization of miR-221, miR-222
and miR-126 and immunohistochemistry of AP2α. Bar, 50 μm. Representative sections from one primary and one metastatic melanoma
specimen are shown. Scrambled and RNU6B correspond to negative and positive controls, respectively. *Po0.05, **Po0.01.
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nuclear export of PLZF are responsible of increased cell
proliferation. In these cells, among a number of candidate
inhibitors, telmisartan was reported to block cell growth by
interfering with the interaction between HB-EGF-C and PLZF.31
Basing on these data and looking for a factor which would
functionally regulate the correct balance of these two couples of
miRs, we focused on AP2α, one of the main transcription factors
involved in melanoma progression from primary to local and
metastatic dissemination. The loss of AP2α was associated with
melanoma transition from radial growth phase to vertical growth
phase and consequently with deregulated levels of the main
tumorigenic factors, as cell adhesion molecules, matrix degrading
enzymes, survival and angiogenic proteins.19 Speciﬁcally AP-2α
acts as a tumor suppressor by activating p21Waf1/Cip1 expression
and inducing cell cycle arrest, but also regulating the expression of
genes involved in cell proliferation (HER2), apoptosis (c-KIT, Bcl-2,
FAS/APO-1, HRK), adhesion (E-cadherin) and invasion/angiogen-
esis (MMP-2, VEGF).22,32,33 Recently, overexpression of AP-2α in
pancreatic cancer cells was also reported to reduce tumor growth
through the regulation of factors such as CDK-4, CDK-6, cyclin-G1,
p27kip1 and p57kip2.34 Few data showed that microRNAs are
regulated themselves by transcription factors. One example is the
miR-17-92 cluster demonstrated as a direct AP-2 target in orofacial
congenital disease.18
All together AP2α appeared to satisfy our requirements in view
of its speciﬁc BSs present on the promoter region of EGFL7,
a secreted protein involved in both physiological and pathological
angiogenesis, which harbor miR-126&126* precursor in its
intron 7. In addition AP2α is reported by TargetScan 6.2 as a
putative target of miR-221&222. Experimental results conﬁrmed
that AP2α expression was directly related with miR-126&126*
levels and inversely with miR-221&222 (Figures 3 and 6), indicating
the miR-221&222-dependent capability to repress AP2α
(Figure 3c). More important, the relative inverse expressions of
these couples of microRNAs were validated on human bioptic
specimens, including nevi and melanomas at early and advanced
stages (Figure 6d and Supplementary Figure 3).
It is interesting to note that in melanoma AP2α expression
displays the same pattern of c-KIT being both genes transcrip-
tionally induced by AP2α itself. Accordingly, both promoters
contain AP2α BSs. In fact AP2α enforced expression, besides
sustaining an autoregulatory loop, resulted able to restore c-KIT in
metastatic melanoma.35 In addition both these melanogenesis-
associated genes showed a striking inverse correlation with
miR-221 and miR-222. Thus, the downregulation of miR-221 and
miR-222 besides unblocking c-KIT and its downstream pathway
clearly induced AP2α (Figure 3).8
To investigate the possibility of miR-126&126* epigenetic
silencing in metastatic melanomas, we treated metastatic
melanoma cell lines with the DNA demethylating 5-aza-dC
and/or with the histone deacetylase TSA. Despite the reported
epigenetic regulation of miR-126 and its hosting gene EGFL7 in
Figure 7. AP2α expression is directly related with EGFL7 and miR-126&126* and inversely with miR-221&222. (a) Evaluation of EGFL7 in AP2α-
transduced Me1402/R and A375M cells at mRNA (left) and protein (right) levels (**Po0.01). (b) Schematic depiction of miR-126&126* and
miR-221&222 coregulatory pathways. The AP2α dependent activation of miR-126&126* and the consequential ADAM9 and MMP7-targeted
downregulation prevent the pro-HB-EGF shedding in normal melanocytes (left). In melanoma the low levels of miR-126&126* unblock ADAM9
and MMP7 resulting in pro-HB-EGF shedding. This proteolytic cleavage originates the intracellular HB-EGF-C fragment that, entering the
nucleus, binds and delocalizes the PLZF transcription factor, thus preventing its repressive function on miR-221&222 transcription. High
amounts of miR-221&222 downregulate AP2α and consequently miR-126&126*, thereby contributing to close the circuitry maintaining
advanced melanoma traits (right).
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primary bladder, prostate and breast tumors, relying on the CpG
island present into Prom2,25,26 we did not obtain any induction
neither of EGFL7 nor of miR-126&126*. In agreement, the
methylation levels detected in differently staged melanomas
and in normal melanocytes did not correlate with miR-126 and
EGFL7 endogenous levels (Figure 1a, Figure 4b and
Supplementary Figure 4). Consequently we focused on the Prom1
region which actually resulted transcriptionally regulated by AP2α.
Speciﬁcally a single BS (BS3), located just upstream to the
translational start site, appeared to cover more than 80% of the
Prom1 activity, as suggested for EGFL7 regulation in endothelial
cells.28
It is ﬁnally worth mentioning the apparent discrepancies in
EGFL7/miR-126&126* regulation in melanoma. In general, the
expression of miR-126&126* appears paralleled by that of EGFL7,11
according to a common mRNA precursor.36 Conversely, the
expression patterns observed in melanoma indicated a more
complex regulation, possibly involving the direct miR-126&126*
targeting of EGFL7, as reported in human endothelial cells37 and
lung cancer.38 Indeed the inverse correlation between EGFL7
protein and miR-126&126* levels detected in advanced melanoma
might derive from their reduced cotranscription, at least partially
resulting from the deﬁciency of AP2α, and in turn from the
reduced targeting of miR-126&126* on EGFL7. EGFL7 modulations
induced by miR-126&126* enforced expression or silencing
supported this idea (Supplementary Figures 4a and b). The
observed dynamic balance might appear one of the possible
escaping mechanisms developed by melanoma. Among many
possible events, we hypothesize that the aberrant CpG methyla-
tion of the AP2α promoter associated with melanoma
transformation39 might unbalance the correct ratio between
the levels of oncosuppressor miR-126&126* and oncogenic
miR-221&222, pushing from miR-126&126* toward miR-221&222
(Figure 7b).
All together our results conﬁrmed the central role of AP2α in
orchestrating melanoma development and/or progression and
further pointed out the signiﬁcance of miR-126&126* and
miR-221&222 in cancer, suggesting this auto-sustaining loop as
a good target for novel therapeutic opportunity.
MATERIALS AND METHODS
Cell lines culture and transduction
Human melanoma cell lines were obtained and characterized as previously
described.8 NHEM from foreskin were obtained from Promocell
(Heidelberg, Germany). All these cell lines were authenticated according
to a standard short tandem repeat-based genotyping and periodically
tested for mycoplasma contamination.
Overexpression of miR-221&222 and miR-126&126* was obtained in
melanoma cells by using lentiviral vectors systems, as already reported.8,9
The AP2α cDNA (NCBI Sequence NM_001032280.2) encompassing its
complete coding sequence was cloned into a variant third-generation
lentiviral vector, pRRL-CMV-PGK- GFP-WPRE, called Tween9 and used for
both infection and transfection experiments. Chemically modiﬁed
antisense oligonucleotides (antagomirs) have been used to inhibit
miR-221 and -222 expression in vitro (Dharmacon Inc., Lafayette, CO,
USA).8 Antagomir-133a was used as a non-targeting control. MiRCURY
locked-nucleic-acid Power Inhibitor knockdown probes for miR-126 and
-126* were obtained from Exiqon (Copenhagen, Denmark; product
numbers #426717-00 and #426718-00). In all the experiments the
locked-nucleic-acid microRNA Inhibitor Negative Control was included
(#199004-00). Transfections were performed using Lipofectamine 2000
(Life Technologies, Carlsbad, CA, USA) according to the manufacturer’s
instructions.
The biopsy melanoma specimens used in this study were obtained from
the archives of the Human Pathology Section, University of Palermo.
Signed informed consent was obtained by patients. Thirty samples,
including nevi as well as primary and metastatic melanomas, were
analyzed. Sampling and handling of human tissue material was carried out
in accordance with the ethical principle of the Declaration of Helsinki.
Cell treatments
The A375M melanoma cell line was treated with Phorbol-12-myristate-13-
acetate for 1 and 2 h at a ﬁnal concentration of 100 nM (Sigma-Aldrich,
Saint Louis, MO, USA).
Where indicated melanoma cell lines were treated with 5 μM of 5-aza-dC
for 48 h or 400 ng/ml TSA for 24 h (Sigma-Aldrich), and with 2.5 μM and
200 ng/ml, respectively, when used together. Media were refreshed
every day.
RNA extraction and qRT–PCR
Total RNA was extracted with NucleoSpin miRNA kit (Macherey-Nagel
GmbH & Co. KG. Düren, Germany.) according to the manufacturer’s
speciﬁcations. qRT–PCR was performed by the TaqMan Technology, using
the ABI PRISM 7700 DNA Sequence Detection System (Life Technologies).
Commercial ready-to-use primers/probe mixes (Assays on Demand
Products, Life Technologies) are listed: miR-221: #000524; miR-222:
#000525; miR-126: #002228; miR-126*: #000451; AP2α: #Hs01029413_m1
and EGFL7: # Hs00211952_m1. Samples were normalized by evaluating
RNU6B (#001093) and GAPDH (#Hs02758991) expression.
Small-interfering RNA
AP2α was speciﬁcally silenced using small interfering RNA (IDT, Leuven,
Belgium). In brief, 24 h after plating, cells were transfected using
Lipofectamine 2000 (Life Technologies) with either DsiAP2α (three
different sequences were utilized: HSC.RNAI.N001032280.12.1, HSC.RNAI.
N001032280.12.2 and HSC.RNAI.N0001032280.12.7) or a DsiRNA scrambled
control (ﬁnal concentration 200 nM). The level of AP2α was analyzed 48 h
after transfection by qRT–PCR and western blot. ADAM9 and MMP7
silencing was performed by using four unique 29-mer shRNA constructs in
retroviral GFP vector, #TG314947 for ADAM9, # TG311438 MMP7 and
#TR30013 for scrambled negative control (OriGene Technologies, Rockville,
MD, USA).
Western blot
Western blot was performed according to standard procedures. Cell lysates
were separated by the precast NuPAGE polyacrylamide gel system (Life
Technologies). When indicated, puriﬁed nuclear and cytoplasmic proteins
were analyzed. In brief, cell pellets from melanoma cell lines were
resuspended in 100–250 μl of Lysis Buffer Cyto (10mM HEPES pH 7.5,
40mM KCl, 3 mM MgCl, 2.5% glycerol and 0.2% NP40) plus protease
inhibitors, maintained on ice for 5 min, vortexed and then centrifuged at
3000 r.p.m. for 5 min at 4 °C. The resultant supernatants represented the
ﬁnal ‘cytoplasmic fractions’. The nuclear pellets were then washed again
with Lysis Buffer Cyto, resuspended in 30–50 μl of Lysis Buffer Nuclei
(20mM HEPES pH 7.5, 40 mM KCl, 420 nM NaCl, 1.5 mM MgCl2, 25% glycerol
and 0.2 mM EDTA) plus protease inhibitors and kept on ice for 20min. After
three freeze/thaw cycles at − 80 °C, the suspensions were centrifuged at
3000 r.p.m. for 10min at 4 °C and the resultant supernatants, representing
the ﬁnal ‘nuclear fractions’, immediately used or aliquoted and frozen at
− 80 °C. Protein concentration was measured by the Biorad protein assay
(Hercules, CA, USA).
Monoclonal antibodies against PI3K(p85b) and OPN (Abcam, Cambridge,
UK, #ab28356, #ab69498) and polyclonal against PLZF (Active Motif,
Belgium, #39987), AP2α, p21, ADAM9 (Santa Cruz Biotechnology, Santa
Cruz, CA, USA, #sc-184-R, #sc-817, sc-50332), EGFL7 (Abcam, Cambridge,
UK, #ab102796) and MMP7 (R&D Systems, Minneapolis, MN, USA,
#MAB9071) were used in accordance to the manufacturer’s instructions.
Nucleolin (Santa Cruz Biotechnology, #sc-8031), α-tubulin and actin
(Sigma-Aldrich, #T5168, #A5441) were used as loading controls. The
expression levels were evaluated by the AlphaView Software (Protein-
simple, SanJose, CA, USA).
Coimmunoprecipitation
Coimmunoprecipitation was conducted as previously described.40 Protein
lysates were immunoprecipitated with polyclonal antibody against
PLZF (Active Motif, #39987) and blots were then probed with either a
polyclonal antibody against HB-EGF (Santa Cruz Biotechnology, #sc-1413)
or PLZF itself.
AP2α controls the balance between miR-126&126* and miR-221&222
N Felli et al
3024
Oncogene (2016) 3016 – 3026 © 2016 Macmillan Publishers Limited
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation assay was performed as previously
described.40 DNA-protein complexes were immunoprecipitated using
anti-AP2α or, as an internal control, the unrelated monoclonal anti-
body against dishvelled-1 (Santa Cruz Biotechnology, #sc-8025). The
recovered DNA was then PCR-ampliﬁed with the primer set listed in
Supplementary Table 1.
Bisulphite modiﬁcation and genomic sequencing
The methylation status of the CpG dinucleotides close to the EGFL7 Prom2
was analyzed. Genomic DNA was isolated from cultured cells using DNeasy
Blood and tissue kit (Qiagen, Valencia, CA, USA) according to manufac-
turer’s instructions and subjected to BisulFlash DNA Modiﬁcation Kit
(Epigentek, Farmingdale, NY, USA). The fragments of interest were
ampliﬁed using the following speciﬁc primer pairs designed with the
MethPrimer program41 fwd, 5′-TTGGGTTTTGTTATGTGGTTTTAG-3′; rev,
5′-AACCCTTTACTAACTTTCAAACCC-3′. PCR products were gel puriﬁed with
the Gel/PCR DNA Fragments Extraction Kit (Geneaid, Biotech Ltd, New
Taipei City, Taiwan), subcloned into the pCR2.1 vector by TA cloning
(Life Technologies) and sequenced via an external sequencing service
(BMR-Genomics, Padova, Italy).
Target analysis
Bioinformatic analysis was performed by using the speciﬁc program
TargetScan (http://www.targetscan.org/). The in silico analysis was
performed by Transfact software (http://www.gene-regulation.com).
Luciferase assay
Luciferase reporter assays were performed as reported.40 In brief, the 3′UTR
of the target gene AP2α predicted to interact with miR-221&222 was PCR
ampliﬁed (from 2916 to 3108) and subcloned into the pGL3 promoter
vector (Promega, Madison, WI, USA). Mutated nucleotides are indicated in
Figure 3b. The wild-type pGL3-3′UTR cotransfected with the control non-
targeting oligonucleotide was considered as 100%.
To analyze the functional roles of the AP2α BSs such as GCCN3GGC or
GCCN3/4GGG (indicated as BS 1–5 in Figure 5a), two DNA fragment
containing the putative regulatory region upstream to miR-126&126* (from
+121 to − 140 nt and from +121 to − 799 nt) were ampliﬁed and cloned in
pGL3 basic (Promega). As controls of speciﬁcity, point mutations were
inserted in the wild-type core-binding sequence for AP2α by using the
QuikChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA).
The sequences of the oligonucleotides are listed in Supplementary Table 2.
Immunohistochemical staining
For immunohistochemical staining, the slides were dewaxed and
rehydrated. After heat-mediated antigenic retrieval using a pH 6.0 sodium
citrate buffer for 30min in thermostatic water bath, the sections were
treated according to the manufacturer’s instructions of the Pierce
Peroxidase Detection kit (Thermo Scientiﬁc, Rockford, IL, USA). The
polyclonal rabbit anti -AP2α (Santa Cruz) was used as primary antibody
at a dilution of 1:200 and the goat anti-rabbit IgG-HRP (656120; Life
Technologies) at 1:3000 dilution as secondary one. Staining was visualized
using the DAB chromogen (Pierce) and the sections were counterstained
with Harris Modiﬁed Hematoxylin. Negative controls were performed by
omission of the primary antibody in each experiment. Slides were
evaluated using a Nikon Eclipse E1000 equipped with a Nikon DXM 1200
digital camera with dedicated acquisition software (Nikon ACT-1 v. 2.1; all
from Nikon Instruments, Campi Bisenzio, Firenze, Italy).
In situ miRNA hybridization
In situ detection of miR-221&222 and miR-126 on formalin-ﬁxed parafﬁn-
embedded melanoma samples was essentially performed as described by
miRCURY locked-nucleic-acid microRNA ISH optimization kit (Exiqon).
Statistical analysis
Statistical and frequency distribution analysis was performed by Excel.
Unless otherwise stated, results were representative of at least three
independent experiments. Statistical analysis was performed using the
t-test with Po0.05 deemed statistically signiﬁcant.
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